ArticleBMJ open2025
Evaluating 10 years of premature mortality costs associated with liver cancer: a retrospective economic analysis of productivity loss in Spain.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hepatocellular carcinoma surveillance: a health economic evaluation.Clinical and molecular hepatology · 2026Review
- Development of novel DALY-based indices for assessing productivity loss and resource allocation for liver cancer in the MENA region.Population health metrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the economic burden of premature mortality due to liver cancer in Spain over 10 years (2013-2022) using a retrospective economic analysis.
designA population-based retrospective study using the Human Capital approach.
settingWe analysed national registry data from the Spanish National Institute of Statistics on mortality, employment and wage structure. Sensitivity analyses were conducted using discount rates of 0%, 3% and 6%.
participantsAll individuals who died from liver cancer between 2013 and 2022, with a focus on the working-age population under 65 years of age. PRIMARY AND SECONDARY OUTCOME MEASURES: Primary outcomes included years of potential life lost (YPLL), years of potential labour productive life lost (YPLPLL) and associated productivity losses due to premature liver cancer mortality. Secondary outcomes involved trend analyses of productivity loss and YPLL over time, and assessment of sex-specific and age-specific differences in productivity losses.
resultsBetween 2013 and 2022, 36 635 individuals died from liver cancer, including 6622 individuals of working age. This led to 9924-12 068 YPLL annually. The cumulative productivity loss was €12.88 billion (range: €12.52-€13.26 billion).
conclusionsThese findings highlight the substantial economic impact of liver cancer mortality in Spain and underscore the importance of targeted prevention and screening programmes for high-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.